This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.
Bruker (BRKR) Expands Materials Science Research via New Deal
by Zacks Equity Research
Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.
Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University
by Zacks Equity Research
Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
by Zacks Equity Research
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
by Zacks Equity Research
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.
Bruker (BRKR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Investors Should Buy Bruker (BRKR) Stock Now
by Zacks Equity Research
The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.
Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG
by Zacks Equity Research
Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.
Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter
by Zacks Equity Research
Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems
by Zacks Equity Research
Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR), backed by the performance of the CALID and NANO groups and strength in acquisitions.
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 4.17% and 5.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 8.11% and 0.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.
Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023
by Zacks Equity Research
Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
by Zacks Equity Research
Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.